Will an Era of Clinical Trials Without Liver Biopsy Arrive?
The FDA recently announced it is considering non-invasive surrogate endpoints for clinical trials of treatments for metabolic dysfunction-associated steatohepatitis (MASH). MASH, a severe form of metabolic dysfunction-associated fatty liver disease, occurs when fat accumulation in the liver causes inflammation and…
